Hepatitis C virus-specific immune responses in noninjecting drug users

Journal of Viral Hepatitis

Volumn 19, Issue 8, 2012, Pages 554-559

  Zeremski, Maz ^a   Makeyeva, J ^a   Arasteh, K ^b   Des Jarlais, D C ^b   Talal, A H ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b BETH ISRAEL MEDICAL CENTER   (United States)

Author keywords

antibody; cellular immunity; ELISpot; serological immunity

Indexed keywords

GAMMA INTERFERON; HEPATITIS C ANTIBODY;

ADULT; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ABUSE; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNE RESPONSE; MALE; PREVALENCE; PRIORITY JOURNAL; REVIEW; SCREENING TEST; SEROLOGY; SEXUAL BEHAVIOR; VIRUS GENOME;

ADULT; DRUG USERS; ENZYME-LINKED IMMUNOSPOT ASSAY; FEMALE; HEPACIVIRUS; HEPATITIS C; HEPATITIS C ANTIBODIES; HUMANS; INTERFERON-GAMMA; MALE; MIDDLE AGED; QUESTIONNAIRES; RISK FACTORS; SEXUAL BEHAVIOR; T-LYMPHOCYTES;

EID: 84863724055     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2011.01573.x     Document Type: Review

References (28)

1. Afdhal NH,. The natural history of hepatitis C. Semin Liver Dis 2004; 24 (Suppl 2): 3-8.
2. Shepard CW, Finelli L, Alter MJ,. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005; 5: 558-567.
3. Chak E, Talal AH, Sherman KE, Schiff ER, Saab S,. Hepatitis C virus infection in the United States: an estimate of true prevalence. Liver Int 2011; 31: 1090-1101.
4. Hahn JA, Page-Shafer K, Lum PJ, et al. Hepatitis C virus seroconversion among young injection drug users: relationships and risks. J Infect Dis 2002; 186: 1558-1564.
5. Thorpe LE, Ouellet LJ, Hershow R, et al. Risk of hepatitis C virus infection among young adult injection drug users who share injection equipment. Am J Epidemiol 2002; 155: 645-653.
6. Des Jarlais DC, Diaz T, Perlis T, et al. Variability in the incidence of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus infection among young injecting drug users in New York City. Am J Epidemiol 2003; 157: 467-471.
7. Judd A, Hickman M, Jones S, et al. Incidence of hepatitis C virus and HIV among new injecting drug users in London: prospective cohort study. BMJ 2005; 330: 24-25.
8. Hagan H, Pouget ER, Des Jarlais DC, Lelutiu-Weinberger C,. Meta-regression of hepatitis C virus infection in relation to time since onset of illicit drug injection: the influence of time and place. Am J Epidemiol 2008; 168: 1099-1109.
9. Lelutiu-Weinberger C, Pouget ER, Des Jarlais DD, et al. A meta-analysis of the hepatitis C virus distribution in diverse racial/ethnic drug injector groups. Soc Sci Med 2009; 68: 579-590.
10. Mehta SH, Astemborski J, Kirk GD, et al. Changes in blood-borne infection risk among injection drug users. J Infect Dis 2011; 203: 587-594.
11. Scheinmann R, Hagan H, Lelutiu-Weinberger C, et al. Non-injection drug use and Hepatitis C Virus: a systematic review. Drug Alcohol Depend 2007; 89: 1-12.
12. Caiaffa WT, Zocratto KF, Osimani ML, et al. Hepatitis C virus among non-injecting cocaine users (NICUs) in South America: can injectors be a bridge? Addiction 2011; 106: 143-151.
13. Hermida M, Ferreiro MC, Barral S, Laredo R, Castro A, Diz Dios P,. Detection of HCV RNA in saliva of patients with hepatitis C virus infection by using a highly sensitive test. J Virol Methods 2002; 101: 29-35.
14. Maticic M, Poljak M, Kramar B, et al. Detection of hepatitis C virus RNA from gingival crevicular fluid and its relation to virus presence in saliva. J Periodontol 2001; 72: 11-16.
15. McMahon JM, Simm M, Milano D, Clatts M,. Detection of hepatitis C virus in the nasal secretions of an intranasal drug-user. Ann Clin Microbiol Antimicrob 2004; 3: 6.
16. Villa PD,. Midfacial complications of prolonged cocaine snorting. J Can Dent Assoc 1999; 65: 218-223.
17. Post JJ, Pan Y, Freeman AJ, et al. Clearance of hepatitis C viremia associated with cellular immunity in the absence of seroconversion in the hepatitis C incidence and transmission in prisons study cohort. J Infect Dis 2004; 189: 1846-1855.
18. Takaki A, Wiese M, Maertens G, et al. Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nat Med 2000; 6: 578-582.
19. Koziel MJ, Wong DK, Dudley D, Houghton M, Walker BD,. Hepatitis C virus-specific cytolytic T lymphocyte and T helper cell responses in seronegative persons. J Infect Dis 1997; 176: 859-866.
20. Bronowicki JP, Vetter D, Uhl G, et al. Lymphocyte reactivity to hepatitis C virus (HCV) antigens shows evidence for exposure to HCV in HCV-seronegative spouses of HCV-infected patients. J Infect Dis 1997; 176: 518-522.
21. Scognamiglio P, Accapezzato D, Casciaro MA, et al. Presence of effector CD8 + T cells in hepatitis C virus-exposed healthy seronegative donors. J Immunol 1999; 162: 6681-6689.
22. Freeman AJ, Ffrench RA, Post JJ, et al. Prevalence of production of virus-specific interferon-gamma among seronegative hepatitis C-resistant subjects reporting injection drug use. J Infect Dis 2004; 190: 1093-1097.
23. Zeremski M, Shu MA, Brown Q, et al. Hepatitis C virus-specific T-cell immune responses in seronegative injection drug users. J Viral Hepat 2009; 16: 10-20.
24. Mizukoshi E, Eisenbach C, Edlin BR, et al. Hepatitis C virus (HCV)-specific immune responses of long-term injection drug users frequently exposed to HCV. J Infect Dis 2008; 198: 203-212.
25. Des Jarlais DC, Arasteh K, Perlis T, et al. Convergence of HIV seroprevalence among injecting and non-injecting drug users in New York City. AIDS 2007; 21: 231-235.
26. Ratner MS, (Ed). Crack Pipe as Pimp: An Ethnographic Study of Sex for Crack Exchanges. Lantham, MD: Lexington Books, 1992.
27. Kall KI,. Effects of amphetamine on sexual behavior of male i.v. drug users in Stockholmâa pilot study. AIDS Educ Prev 1992; 4: 6-17.
28. Thimme R, Oldach D, Chang KM, Steiger C, Ray SC, Chisari FV,. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med 2001; 194: 1395-406.